Results 51 to 60 of about 43,721 (231)

Cryo-EM Structure of Human Cannabinoid Receptor CB2-Gi Signaling Complex

Cell, 2020
SUMMARY Drugs selectively targeting CB2 hold promise for treating neurodegenerative disorders, inflammation and pain while avoiding psychotropic side effects mediated by CB1.
C. Xing, Y. Zhuang, Ting-Hai Xu, Zhiwei Feng, X. E. Zhou, Maozi Chen, Lei Wang, Xing Meng, Ying Xue, Junmei Wang, Heng Liu, T. Mcguire, Gongpu Zhao, K. Melcher, Cheng Zhang, H. Xu, X. Xie   +16 more
semanticscholar   +1 more source

Toxicokinetic modelling of the synthetic cannabinoid 5F‐MDMB‐P7AICA and its main metabolite in pigs following pulmonary administration

British Journal of Clinical Pharmacology, EarlyView.
Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr, Christiane Dings, Omar Zaher, Frederike Nordmeier, Nadja Walle, Matthias W. Laschke, Michael D. Menger, Peter H. Schmidt, Markus R. Meyer, Thorsten Lehr, Nadine Schaefer   +10 more
wiley   +1 more source

Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212–2 in renal cell carcinoma

BMC Cancer, 2018
Background The anti-tumor properties of cannabinoids have been investigated in many in vitro and in vivo studies. Many of these anti-tumor effects are mediated via cannabinoid receptor types 1 and 2 (CB1 and CB2), comprising the endocannabinoid system ...
Mohammed I. Khan, Anna A. Sobocińska, Klaudia K. Brodaczewska, Katarzyna Zielniok, Malgorzata Gajewska, Claudine Kieda, Anna M. Czarnecka, Cezary Szczylik   +7 more
doaj   +1 more source

Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor

Molecular Metabolism, 2014
Brain mitochondrial activity is centrally involved in the central control of energy balance. When studying mitochondrial functions in the brain, however, discrepant results might be obtained, depending on the experimental approaches.
Etienne Hebert-Chatelain, Leire Reguero, N. Puente, B. Lutz, F. Chaouloff, R. Rossignol, P. Piazza, G. Bénard, P. Grandes, G. Marsicano   +9 more
semanticscholar   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Prediction of essential binding domains for the endocannabinoid N-arachidonoylethanolamine (AEA) in the brain cannabinoid CB1 receptor.

PLoS ONE, 2021
Δ9-tetrahydrocannabinol (Δ9-THC), the main active ingredient of Cannabis sativa (marijuana), interacts with the human brain cannabinoid (CB1) receptor and mimics pharmacological effects of endocannabinoids (eCBs) like N-arachidonylethanolamide (AEA). Due
Joong-Youn Shim
doaj   +1 more source

Significance of Cannabinoid CB1 Receptors in Improgan Antinociception [PDF]

The Journal of Pain, 2007
Improgan is a congener of the H(2) antagonist cimetidine, which produces potent antinociception. Because a) the mechanism of action of improgan remains unknown and b) this drug may indirectly activate cannabinoid CB(1) receptors, the effects of the CB(1) antagonist/inverse agonist rimonabant (SR141716A) and 3 congeners with varying CB(1) potencies were
Neal C, Gehani, Julia W, Nalwalk, Raj K, Razdan, Billy R, Martin, Xufung, Sun, Mark, Wentland, Mary E, Abood, Lindsay B, Hough   +7 more
openaire   +2 more sources

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Subsynaptic Distribution, Lipid Raft Targeting and G Protein-Dependent Signalling of the Type 1 Cannabinoid Receptor in Synaptosomes from the Mouse Hippocampus and Frontal Cortex

Molecules, 2021
Numerous studies have investigated the roles of the type 1 cannabinoid receptor (CB1) in glutamatergic and GABAergic neurons. Here, we used the cell-type-specific CB1 rescue model in mice to gain insight into the organizational principles of plasma ...
Miquel Saumell-Esnaola, Sergio Barrondo, Gontzal García del Caño, María Aranzazu Goicolea, Joan Sallés, Beat Lutz, Krisztina Monory   +6 more
doaj   +1 more source

Elevated Brain Cannabinoid CB1 Receptor Availability in Posttraumatic Stress Disorder: A Positron Emission Tomography Study

Molecular Psychiatry, 2013
Endocannabinoids and their attending cannabinoid type 1 (CB1) receptor have been implicated in animal models of post-traumatic stress disorder (PTSD). However, their specific role has not been studied in people with PTSD.
A. Neumeister, M. Normandin, R. Pietrzak, D. Piomelli, M. Zheng, A. Gujarro-Anton, M. Potenza, C. Bailey, Shu-Fei Lin, S. Najafzadeh, J. Ropchan, S. Henry, S. Corsi-Travali, R. Carson, Yiyun Huang   +14 more
semanticscholar   +1 more source